Digital success doesn ’t start with the tech
We all know that the biggest hurdle for any transformation project is culture. No wonder then that many of us working within digital transformation have hoped to open minds and inspire a new way of working through big, buzzy projects.
There ’s now even a blueprint for this type of innovation: find a tech partner, design a pilot with a trending technology, and ‘signal’ to peers, rivals and shareholders that you’re embracing the future with a flashy press release.
But when we sat down with Dan Rothman the Chief Digital Officer, Dainippon Sumitomo Pharma and Milind Kamkolkar, Chief Digital Officer, Cell...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news
Digital success doesn ’t start with the tech
We all know that the biggest hurdle for any transformation project is culture. No wonder then that many of us working within digital transformation have hoped to open minds and inspire a new way of working through big, buzzy projects.
There ’s now even a blueprint for this type of innovation: find a tech partner, design a pilot with a trending technology, and ‘signal’ to peers, rivals and shareholders that you’re embracing the future with a flashy press release.
But when we sat down with Dan Rothman the Chief Digital Officer, Dainippon Sumitomo Pharma and Milind Kamkolkar, Chief Digital Officer, Cell...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news
Seizing the moment in digital
One of the most remarkable changes driven by the pandemic has been the rapid transition from face-to-face interaction to digital communication across every aspect of our lives. Even the most tech-phobic among us have been forced to embrace what digital technology has to offer.
This huge shift across all demographics and geographies could provide an unforeseen benefit to pharma, an industry that has been ripe for different types of engagement, but which has until now been held back from embracing them. The pandemic is accelerating the rollout of digital of platforms and services, says Abel Archundia, SVP, Global Hea...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
Seizing the moment in digital
One of the most remarkable changes driven by the pandemic has been the rapid transition from face-to-face interaction to digital communication across every aspect of our lives. Even the most tech-phobic among us have been forced to embrace what digital technology has to offer.
This huge shift across all demographics and geographies could provide an unforeseen benefit to pharma, an industry that has been ripe for different types of engagement, but which has until now been held back from embracing them. The pandemic is accelerating the rollout of digital of platforms and services, says Abel Archundia, SVP, Global Hea...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
Seizing the moment in digital
One of the most remarkable changes driven by the pandemic has been the rapid transition from face-to-face interaction to digital communication across every aspect of our lives. Even the most tech-phobic among us have been forced to embrace what digital technology has to offer.
This huge shift across all demographics and geographies could provide an unforeseen benefit to pharma, an industry that has been ripe for different types of engagement, but which has until now been held back from embracing them. The pandemic is accelerating the rollout of digital of platforms and services, says Abel Archundia, SVP, Global Hea...
Source: EyeForPharma - May 28, 2020 Category: Pharmaceuticals Authors: Katie Osborne Source Type: news
Michel Pairet, Member of Board of Managing Directors at Boehringer Ingelheim on COVID-19 research
Pr écis: eyeforpharma speaks to Michel Pairet, Member of Board of Managing Directors at Boehringer Ingelheim on their COVID-19 research.YouTube URL: https://www.youtube.com/watch?v=fN9Q6bEebMM&feature=youtu.beVideo Thumbnail Image: Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercial (Source: EyeForPharma)
Source: EyeForPharma - April 29, 2020 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
Michel Pairet, EVP at Boehringer Ingelheim on COVID-19 research
Pr écis: eyeforpharma speaks to Michel Pairet, EVP at Boehringer Ingelheim on their COVID-19 research.YouTube URL: https://www.youtube.com/watch?v=-PcjUccZly4&feature=youtu.beVideo Thumbnail Image: Channels: Access and EvidenceMedicalMultichannelPatients and MedicalClinicalColumnCommercial (Source: EyeForPharma)
Source: EyeForPharma - April 29, 2020 Category: Pharmaceuticals Authors: Izzy Gladstone Source Type: news
Customer centricity in a changed world
Few or no reps on the road, patients confined en masse to their homes and a healthcare and economic emergency of which we can still only guess the scale and duration.
It is a situation that pharma ’s marketing folk never expected, never planned for and one which our panel discuss in depth on day one of eyeforpharma’s Philadelphia Virtual conference in the panel session on customer centricity. Marketing departments face a daunting challenge. More used to planning for slowly emerging trends, they are being forced by the pandemic situation to react in real time to increase their digital engagement capabilities,...
Source: EyeForPharma - April 20, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Customer centricity in a changed world
Few or no reps on the road, patients confined en masse to their homes and a healthcare and economic emergency of which we can still only guess the scale and duration.
It is a situation that pharma ’s marketing folk never expected, never planned for and one which our panel discuss in depth on day one of eyeforpharma’s Philadelphia Virtual conference in the panel session on customer centricity. Marketing departments face a daunting challenge. More used to planning for slowly emerging trends, they are being forced by the pandemic situation to react in real time to increase their digital engagement capabilities,...
Source: EyeForPharma - April 20, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Customer centricity in a changed world
Few or no reps on the road, patients confined en masse to their homes and a healthcare and economic emergency of which we can still only guess the scale and duration.
It is a situation that pharma ’s marketing folk never expected, never planned for and one which our panel discuss in depth on day one of eyeforpharma’s Philadelphia Virtual conference in the panel session on customer centricity. Marketing departments face a daunting challenge. More used to planning for slowly emerging trends, they are being forced by the pandemic situation to react in real time to increase their digital engagement capabilities,...
Source: EyeForPharma - April 20, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Breaking new ground in healthcare data
The pandemic crisis has been focusing minds in healthcare and demonstrating the possibilities to innovate faster.
Pharma should remember this in the aftermath, says Sanofi Pasteur ’s David Loew, not least because, given the economic damage of a near global lockdown, governments can soon be expected to be on the hunt for savings from pharma. “Given the economic downturn we have to expect there will be price pressures,” says Loew in his keynote on day one of the eyeforpharma Philadelphia Virtual conference (available free to anyone who registers).
Pharma, healthcare providers and health ministries have a g...
Source: EyeForPharma - April 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Breaking new ground in healthcare data
The pandemic crisis has been focusing minds in healthcare and demonstrating the possibilities to innovate faster.
Pharma should remember this in the aftermath, says Sanofi Pasteur ’s David Loew, not least because, given the economic damage of a near global lockdown, governments can soon be expected to be on the hunt for savings from pharma. “Given the economic downturn we have to expect there will be price pressures,” says Loew in his keynote on day one of the eyeforpharma Philadelphia Virtual conference (available free to anyone who registers).
Pharma, healthcare providers and health ministries have a g...
Source: EyeForPharma - April 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
Breaking new ground in healthcare data
The pandemic crisis has been focusing minds in healthcare and demonstrating the possibilities to innovate faster.
Pharma should remember this in the aftermath, says Sanofi Pasteur ’s David Loew, not least because, given the economic damage of a near global lockdown, governments can soon be expected to be on the hunt for savings from pharma. “Given the economic downturn we have to expect there will be price pressures,” says Loew in his keynote on day one of the eyeforpharma Philadelphia Virtual conference (available free to anyone who registers).
Pharma, healthcare providers and health ministries have a g...
Source: EyeForPharma - April 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news
